Citations

Clear

3030 citation(s) found for "Susan, M".

Structures and functions of the limited natural polyclonal antibody response to parvovirus infection
Adu, Oluwafemi F. , Lee, Hyunwook , Früh, Simon P. , Schoenle, Marta V., Weichert, Wendy S. , Parrish, Colin R. , Hafenstein, Susan L, Parrish, Colin R , Flyak, Andrew I. , Hafenstein, Susan

Mayo Clinic

Proceedings of the National Academy of Sciences | February 14, 2025 | Volume: 122 | Issue: 8 | Pages: No page available

10.1073/pnas.2423460122 | PMID 39951487 Get It

Host antibody responses are key components in the protection of animals against pathogens, yet the defining properties of viral antigens and induction of B cell responses that result in varied protection are still poorly understood. Parvoviruses are simple molecular structures that display 60 repeated motifs on their capsid surface, and rapidly induce strong antibody responses that protect animals from infection. We recently showed that following canine parvovirus infection of its natural host, the polyclonal response in the sera contained only two or three dominant antibodies that bound two epitopes on the capsid. Here, we characterize key antibodies present in that immune response, identifying their sequences, defining their binding properties on the capsid by cryoelectron microscopic (cryoEM) analysis, and testing their effects on viral infectivity. Two antibodies sharing the same heavy chain bound to the side of the capsid threefold spike (B-site), while another distinct antibody bound close to the threefold axis (A-site). The epitopes of these antibodies overlapped the binding site of the host receptor, the transferrin receptor type-1, but to varying degrees. The antibodies varied widely in their neutralization efficiencies as either immunoglobulins (IgGs) or monomeric antigen-binding fragments (Fabs), which was consistent with their ability to compete for the receptor. The monoclonal antibodies characterized here matched the structures from the cryoEM analysis of polyclonal sera, including those present in a different dog than the monoclonal source. This shows that after infection, a focused response to the viral antigen is produced that protects against infection.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Inaba, Hiroto , Teachey, David T. , Annesley, Colleen , Batra, Sandeep , Beck, Jill C., Cooper, Stacy , Dallas, Mari , Oliveira, Satiro De , Kelly, Kara M. , Kohorst, Mira A. , Kutny, Matthew A. , Lee‐Miller, Cathy , Ludwig, Kathleen , Madden, Lisa, Maloney, Kelly W. , Massaro, Stephanie, Morocco, Perry , Muller, Brad, Murphy, Lindsey , Nardi, Valentina , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Wong, Victor , Yanik, Gregory A. , Stehman, Katie, Inaba, Hiroto , Colace, Susan I. , Kitko, Carrie L. , Lacayo, Norman James , Mangum, David Spencer , McCall, David C. , Shah, Bijal , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 41-62

10.6004/jnccn.2025.0006 | PMID 39938467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.
Capacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study
Matheny, Michael E. , Perkins, Amy M. , Rieger‐Christ, Kimberly , Ross, Joseph S. , Mao, Jialin , Sedrakyan, Art , Shah, Nilay D. , Mourtzinos, Arthur, Bartlett, Victoria , Solotke, Michael T. , Pandya, Sameer, Aryal, Suvekshya , Cho, Ahra, Frankenberger, Edward , Park, Daniel , Bostrom, Danielle, Robbins, Susan P. , Yustein, Aron, Trabuco, Emanuel C. , Frankenberger, Edward A , Chughtai, Bilal , Trabuco, Emanuel C , Matheny, Michael , Ross, Joseph S , Winter, Robert, Reynolds, William M. , Schulz, Wade L. , Robbins, Susan, Yustein, Aron S.

Mayo Clinic

BMJ Surgery, Interventions, & Health Technologies | February 12, 2025 | Volume: 7 | Issue: 1 | Pages: e000193

10.1136/bmjsit-2023-000193 | PMID 39949784 Get It

Objectives To evaluate the feasibility for use of electronic health record (EHR) data in conducting adverse event surveillance among women who received mid-urethral slings (MUS) to treat stress urinary incontinence (SUI) in five health systems. Design Retrospective observational study using EHR data from 2010 through 2021. Women with a history of MUS were identified using common data models; a common analytic code was executed at each site. A manual chart review was conducted in a per-site random patient subset to establish a reference standard. Automated text processing (Text Processed Integrated (TPI)) was developed and evaluated at each site to determine the surgical approach and synthetic mesh implantation. Patients were characterized and surgical outcomes were ascertained over 730 subsequent days. Setting Five large tertiary care academic medical centers. Participants Across five health systems, 9,906 eligible patients (mean age 57–60 per site) were identified. Main outcome measures Determination of surgical approach, synthetic mesh implantation, and assessment of the duration of surveillance for mortality and reoperation rates following MUS implantation. Results In the TPI cohort analysis, 3,331 patients were identified. Surgical approach per site was retropubic (42% to 77%), transobturator (6% to 44%), single incision (0% to 24%), and adjustable sling (0% to <4%). Concordance rates for TPI using chart review were 71%–90% at each site for the surgical approach and 28%–85% for synthetic mesh implantation. Patient follow-up observation rates for mortality and reoperation ranged from 22% to 36% at 90 days, 15% to 30% at 365 days, and 8% to 19% at 730 days. Conclusion Using EHR data alone, identification of medical devices and surgical approaches was feasible among women with MUS surgery for SUI, but long-term follow-up ascertainment rates were low. Medical device surveillance using EHR data should be evaluated in the context of the clinical use case, as applicability may vary.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11

10.6004/jnccn.2025.0007 | PMID 39938471 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida
Rogina, Blanka , Anderson, Rozalyn M. , Curan, Sean, Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Duque, Gustavo , Howlett, Susan E. , Austad, Steven N. , Korfhage, Justin , Christensen, Kaare , Carey, James R. , Bell, Justice, Gomes, Ana P. , Dixit, Vishwa Deep , Sen, Payel , Imai, Shin‐ichiro , Valdez, Gregorio , Orr, Miranda E. , Jones, Leanne , Castillo-Azofeida, David, Bonaguidi, Michael A. , Suh, Yousin , Duncan, Francesca E. , C, Weigler G Perry, Burkewitz, Kristopher , Zhou, Kai , Bouhrara, Mustapha , Kolind, Shannon , Dean, Doug, Pálovics, Róbert , Niedernhofer, Laura J. , Fan, Rong , Bueckle, Andreas , Kapahi, Pankaj , Jiang, Nisi , Diaz, Jose , Mishra, Sidharth P. , Ralmundo, Nuno, Banarjee, Reema , Allsopp, Richard , Curran, Sean P. , Anderson, Rozalyn M , Curran, Sean P , Yousefzadeh, Matthew J , Duque, Gustavo , Howlett, Susan , Austad, Steven , Demuth, Ilja , Gerstorf, Denis , Abadir, Peter , Christensen, Kaare , Palmer, Allyson, Basisty, Nathan , de Cabo, Rafael , Sen, Payel , Baur, Joseph A , Duncan, Francesca E , Benjamini, Dan , Walker, Keenan A , Dean, Douglas C , Gladyshev, Vadim N , Fan, Rong , Sato, Shogo , Jiang, Nisi , Ashiqueali, Sarah A., Allsopp, Richard , Niedernhofer, Laura J , Kollind, Shannon H , LeBrasseur, Nathan K. , Lombard, David B. , Alberts, Susan C. , Campos, Fernando A. , Palavicini, Juan Pablo , Palmer, Allyson K. , Basisty, Nathan , Cabo, Rafael de , Baur, Joseph A. , Li, Xiaoling , Pletcher, Scott D. , Andersen, Julie Kay , Jones, Leanne, Suh, Yousin , Murray, Anna , Wang, Meng C., Henne, W. Mike , Walker, Keenan A. , Reiter, David A. , Gorbunova, Vera , Gladyshev, Vadim N. , Hurley, Jennifer , Esser, Karyn A. , Ashiqueali, Sarah , Reynolds, Lindsay M. , Zhang, Bohan , Sebastiani, Paola , Monti, Stefano , Schork, Nicholas J. , Rappaport, Noa

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 11, 2025 | Volume: 80 | Issue: 5 | Pages: No page available

10.1093/gerona/glaf026 | PMID 39932386 Get It

Abstract The aging process is universal, and it is characterized by a progressive deterioration and decrease in physiological function leading to decline on the organismal level. Nevertheless, a number of genetic and nongenetic interventions have been described, which successfully extend healthspan and lifespan in different species. Furthermore, a number of clinical trials have been evaluating the feasibility of different interventions to promote human health. The goal of the annual Biological Sciences Section of the Gerontological Society of America meeting was to share current knowledge of different topics in aging research and provide a vision of the future of aging research. The meeting gathered international experts in diverse areas of aging research including basic biology, demography, and clinical and translational studies. Specific topics included metabolism, inflammaging, epigenetic clocks, frailty, senescence, neuroscience, stem cells, reproductive aging, inter-organelle crosstalk, comparative transcriptomics of longevity, circadian clock, metabolomics, and biodemography.
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
Petersen, Ronald C. , Graf, Ana, Brady, Chris, Santi, Susan De , Florian, Hana , Landen, Jaren W., Pontecorvo, Mike, Randolph, Christopher , Sink, Kaycee M. , Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Brady, Chris

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | February 11, 2025 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/trc2.70038 | PMID 39935618 Get It

Abstract The design of clinical trials in Alzheimer's disease (AD) must consider the development of new plasma, cerebrospinal fluid (CSF), and imaging biomarkers. They must also define clinically meaningful outcomes for patients and set endpoints that measure these outcomes accurately. With the accelerated United States Food and Drug Administration (FDA) approval of the first anti‐amyloid, disease‐modifying treatment for AD, a monoclonal antibody called aducanumab, the landscape of clinical trial design is evolving. Enrolment in clinical trials may be impacted by the availability of this and other treatments, and trial design must take into consideration that patients may desire a disease‐modifying treatment rather than potentially being randomized to the placebo arm. The Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting discussed the consideration of well‐defined AD staging criteria in protocol design and how they influence more standardized inclusion/exclusion criteria for trials, as well as what constitutes meaningful differentiation between the stages. Discussion explored the current state of knowledge regarding biomarkers and how they can inform AD staging criteria, as many trials are now designed based on specific biomarker features, further underscoring the importance of coordinating AD staging criteria and biomarkers. The relationship between cognition and biomarkers has been studied and this must continue as trials move forward. Researchers, patients, clinicians, regulatory scientists, and payers discussed the state of the field as well as the future of symptomatic Alzheimer's disease clinical trials. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from academia and industry as well as patients, care partners, clinicians, regulators, and payers to discuss the topic of operationalizing selection criteria for clinical trials and the role of biomarkers. Well‐defined Alzheimer's disease (AD) staging criteria are an important consideration in study protocol design. Staging criteria and biomarkers must be coordinated to yield high‐quality clinical trial results that have meaning for patients with AD by selecting a population most likely to benefit from a specific treatment.
Effectiveness and Determinants of Remission in Transsphenoidal Surgery for Prolactinoma: A Retrospective Analysis
Iyer, Harshvardhan , Safa, Adrian , Ariwodo, Ogechukwu, Collela, Filippo, Nieto-Gutierrez, Astrid, McKevitt, Chase , Sanchez-Garavito, Emiliano, Llano, Juan Pablo Navarro Garcia de, Donaldson, Angela M. , Olomu, Osarenoma , Hinojosa, Alfredo Quinones, Samson, Susan L. , Chaichana, Kaisorn L. , Iyer, Harshvardhan G , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803766 Get It

Patient Experience and Adherence to a Fluid Restriction Protocol after Transsphenoidal Surgery
Perez‐Vega, Carlos , Sánchez-Garavito, Jesús E. , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Samson, Susan L. , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803054 Get It

Selective Resection of the Medial Wall of the Cavernous Sinus: A Prospective Study
Oberman, Dan Zimelewicz , Sanchez-Garavito, Emiliano, Perez‐Vega, Carlos , Donaldson, Angela M. , Olomu, Osarenoma , Graepel, Stephen , Edgar, Mark , Hinojosa, Alfredo Quinones, Chaichana, Kaisorn L. , Samson, Susan L. , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803025 Get It